Skip to main content
. 2020 Nov 16;12(11):3382. doi: 10.3390/cancers12113382

Figure 7.

Figure 7

Kaplan–Meier analysis of progression-free survival (PFS) patients in stage III–IV ovarian cancer patients (n = 29). (A) Patients with higher cfDNA concentration had significantly worse PFS (p = 0.005 by log-rank test). (B) Presence/absence of pathogenic mutation did not significantly associate with PFS (p = 0.864). (C) bTMB level was not significantly associated with PFS (p = 0.313).